Fig. 4: Decreased de novo lipogenesis in LKO mice.
From: Hepatic SREBP signaling requires SPRING to govern systemic lipid metabolism in mice and humans
a Scheme depicting the experimental design used to measure in vivo DNL. Male, 8-week-old control (n = 8) and LKO mice (n = 7) were given ad libitum access to water containing [13C]acetate for 3 days as described in the “Methods” section. Liver was collected and the incorporation of [13C]acetate into the (b–e) indicated fatty acids was determined. p-values: C16:0 (0.006); C16:1 (0.029); C18:0 (0.002); C18:1 (0.019). f Primary hepatocytes were isolated from control and LKO mice. Incorporation of [14C]acetate into cholesterol was determined as described without or with 5 µM simvastatin and 100 µM mevalonate to inhibit HMGCR (three independent experiments done with two mice each; in total n = 6 mice/group). p-value: 0.0004. g Male, 8-week-old control (n = 6) and LKO (n = 7) mice were injected with poloxamer 407 to inhibit peripheral LPL activity as described in the methods section. Subsequently, plasma was collected at the indicated times and the triglyceride level determined. p-value: 0.0023. h The area under the curve of triglycerides over time is plotted. p-value: 0.034 (i–l) Hepatic content of (i, k) cholesterol (p-value: male (0.0035); female (0.0012)) and (j, l) triglycerides (p-value: male (0.037); female (0.0002)) was determined in (i, j) male and (k, l) female control and LKO mice (male: n = 8/group; female n = 6/group). g Each point depicts the mean ± SD. b–f, h–l Box plots show the median (middle line), 25th, 75th percentile (box) and minimum and maximum values (whiskers). *p < 0.05, **p < 0.01, ***p < 0.001 analyzed by (b–e, h–l) two-tailed Welch’s t-test, (f) one-way ANOVA with Holm-Sidak post hoc analysis, or (g) two-way ANOVA with Holm-Sidak post hoc analysis. Source data are provided as a Source Data file.
